美东时间1月20日,诺和诺德与Aspect Biosystems宣布双方合作进入新阶段,共同开发用于糖尿病治疗的先进细胞药物。自2023年起,Aspect与诺和诺德便开始合作研发细胞药物,旨在替代、修复或补充生物功能,以实现真正的疾病修饰疗法。此次合作成果推进,加速了双方研发重疾病药物的共同使命。根据合作协议,Aspect获得了诺和诺德的干细胞衍生胰岛细胞及低免疫细胞工程技术的相关权利,并将主导这...
Source Link美东时间1月20日,诺和诺德与Aspect Biosystems宣布双方合作进入新阶段,共同开发用于糖尿病治疗的先进细胞药物。自2023年起,Aspect与诺和诺德便开始合作研发细胞药物,旨在替代、修复或补充生物功能,以实现真正的疾病修饰疗法。此次合作成果推进,加速了双方研发重疾病药物的共同使命。根据合作协议,Aspect获得了诺和诺德的干细胞衍生胰岛细胞及低免疫细胞工程技术的相关权利,并将主导这...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.